Brand Name
Elelyso
Generic Name
Taliglucerase
View Brand Information FDA approval date: May 01, 2012
Classification: Hydrolytic Lysosomal Glucocerebroside-specific Enzyme
Form: Injection
What is Elelyso (Taliglucerase)?
ELELYSO is indicated for the treatment of patients 4 years of age and older with a confirmed diagnosis of Type 1 Gaucher disease. ELELYSO is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for the treatment of patients 4 years and older with a confirmed diagnosis of Type 1 Gaucher disease .
Approved To Treat
Top Global Experts
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
There is no clinical trials being done for this treatment